Davis Matthew W.
Reporting owner on Forms 3, 4 and 5, CIK 2094283.
Davis Matthew W. reported on 1 issuer in 2 filings, the latest a Form 4 filed 2026-11-16.
Issuers
| Issuer | Roles in the latest filing | Filings | Last filed |
|---|---|---|---|
| AQST · Aquestive Therapeutics, Inc.CIK 1398733 | officer (Chief Development Officer) | 2 | 2026-11-16 |
Transactions and holdings
Every row of the person's Forms 3, 4 and 5, newest first, with the price and the amount owned after the row as filed.
| Security | Date | Code | Shares | Price | Owned after | Filing |
|---|---|---|---|---|---|---|
| AQST · Aquestive Therapeutics, Inc.Common Stock | 2026-11-12 | S sold | -7,197 | $3.5468 | 87,500 | Form 4 |
| AQST · Aquestive Therapeutics, Inc.Common Stock | 2026-11-10 | F withheld for tax | -5,303 | $3.52 | 94,697 | Form 4 |
Filings
The person's Forms 3, 4 and 5, and any 13D or 13G naming it.
| Filing | Subject | Filed | Accepted | Ingested |
|---|---|---|---|---|
| Form 4 0001214659-26-014337 | Aquestive Therapeutics, Inc. | 2026-11-16 | ||
| Form 4 0001214659-26-014000 | Aquestive Therapeutics, Inc. | 2026-11-12 |